Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
Tóm tắt
The aim of this international guideline on dementia was to present a peer‐reviewed evidence‐based statement for the guidance of practice for clinical neurologists, geriatricians, psychiatrists, and other specialist physicians responsible for the care of patients with dementia. It covers major aspects of diagnostic evaluation and treatment, with particular emphasis on the type of patient often referred to the specialist physician. The main focus is Alzheimer's disease, but many of the recommendations apply to dementia disorders in general. The task force working group considered and classified evidence from original research reports, meta‐analysis, and systematic reviews, published before January 2006. The evidence was classified and consensus recommendations graded according to the EFNS guidance. Where there was a lack of evidence, but clear consensus, good practice points were provided. The recommendations for clinical diagnosis, blood tests, neuroimaging, electroencephalography (EEG), cerebrospinal fluid (CSF) analysis, genetic testing, tissue biopsy, disclosure of diagnosis, treatment of Alzheimer's disease, and counselling and support for caregivers were all revised when compared with the previous EFNS guideline. New recommendations were added for the treatment of vascular dementia, Parkinson's disease dementia, and dementia with Lewy bodies, for monitoring treatment, for treatment of behavioural and psychological symptoms in dementia, and for legal issues. The specialist physician plays an important role together with primary care physicians in the multidisciplinary dementia teams, which have been established throughout Europe. This guideline may contribute to the definition of the role of the specialist physician in providing dementia health care.
Từ khóa
Tài liệu tham khảo
Andlin‐Sobocki P, 2005, Cost of disorders of the brain in Europe, European Journal of Dementia, 12, 1
Waldemar G, 2006, Access to diagnostic evaluation and treatment for dementia in Europe, International Journal of Geriatric Psychiatry
Waldemar G, 2000, Diagnosis and management of Alzheimer's disease and related disorders: the role of neurologists in Europe, European Journal of Neurology, 7, 133, 10.1046/j.1468-1331.2000.00030.x
American Psychiatric Association (APA), 1993, Diagnostic and Statistical Manual of Mental Disorders. DSM‐IV
Folstein MF, 1995, Mini‐Mental State. A practical method for grading the cognitive state of patients for the clinician, Journal of Psychiatric Research, 12, 189
Mattis S, 1976, Geriatric Psychiatry: a Handbook for Psychiatrist and Primary Care Physicians, 77
Dubois B, 2002, The ‘5 words’ test: a simple and sensitive test for the diagnosis of Alzheimer's disease, Presse Médicale, 31, 1696
Finkel S, 2000, Behavioral and Psychological Symptoms of Dementia (BPSD): A Clinical and Research Update, 9
Neary D, 1996, Frontotemporal Dementia Current Issues in Neurodegeneration, 31
Hwang TJ, 2004, Alzheimer's Disease and Related Disorders Annual 2004, 71
Gustavson AR, 2004, Alzheimer's Disease. A Physician's Guide to Practical Management, 371
Reisberg B, 1987, Behavioral symptoms in Alzheimer's disease: phenomenology and treatment, Journal of Clinical Psychiatry, 48, 9
Galasko D, 1997, An Inventory to assess activities of daily living for clinical trials in Alzheimer‘s disease, Alzheimer‘s Disease and Associated Disorders, 11, S33, 10.1097/00002093-199700112-00005
DeJong R, 1989, Measurement of quality of life changes in patients with Alzheimer's disease, Clinical Therapy, 11, 545
Fu C, 2004, Comorbidity in dementia: an autopsy study, Archives of Pathology and Laboratory Medicine, 128, 32, 10.5858/2004-128-32-CID
Farina E, 1999, Observations on dementias with possibly reversible symptoms, Aging, 11, 323
Foster GR, 1999, The use of CT scanning in dementia. A systematic review, International Journal of Technology Assessments in Health Care, 15, 406, 10.1017/S0266462399152115
Frisoni GB, 2002, Radial width of the temporal horn: a sensitive measure in Alzheimer disease, American Journal of Neuroradiology, 23, 35
Frisoni GB, 1996, Linear measures of atrophy in mild Alzheimer's disease, American Journal of Neuroradiology, 17, 913
Pucci EBN, 1998, Hippocampus and parahippocampal gyrus linear measurements based on magnetic resonance in Alzheimer's disease, European Journal of Neurology, 39, 16, 10.1159/000007893
Jagust W, 2002, Evidence‐Based Dementia Practice, 162
Jelic V, 1999, Diagnostic accuracies of quantitative EEG and PET in mild Alzheimer's disease, Alzheimer's Reports, 2, 291
Sjögren M, 2001, Tau and Aβ42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values, Clinical Chemistry, 47, 1776, 10.1093/clinchem/47.10.1776
Van Everbroeck B, 2003, A prospective study of CSF markers in 250 patients with possible Creutzfeldt–Jakob disease, Journal of Neurology, Neurosurgery, and Psychiatry, 74, 1210, 10.1136/jnnp.74.9.1210
Lemstra AW, 2001, [Clinical algorithm for cerebrospinal fluid test of 14‐3‐3 protein in diagnosis of Creutzfeldt‐Jacob disease], Nederlands Tijdschrift voor Geneeskunde, 145, 1467
Alzheimer Europe, 2000, Lawnet – Final report
Alzheimer Europe, 2001, Recommendations on How to Improve the Legal Rights and Protection of Adults with Incapacity due to Dementia
Fearnley K, 1999, The Right to Know – Sharing the Diagnosis of Dementia
NICE, 2001, Alzheimer's Disease – Donepezil, Rivastigmine and Galantamine
Clegg A, Clinical and cost‐effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease: a rapid and systematic review, Health Technology Assessments, 5, 1
Le Bars PL, 1997, A placebo‐controlled, double‐blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group, Journal of the American Medical Association, 278, 1327, 10.1001/jama.1997.03550160047037
Tabet N, 2000, Vitamin E for Alzheimer's disease, The Cochrane Database of Systematic Reviews
Craig D, 2004, Rivastigmine for vascular cognitive impairment, Cochrane Database of Systematic Reviews
Ditzler K, 1991, Efficacy and tolerability of memantine in patients with dementia syndrome. A double‐blind, placebo controlled trial, Arzneimittel-Forschung, 41, 773
Görtelmeyer R, 1992, Memantine in the treatment of mild to moderate dementia syndrome. A double‐blind placebo‐controlled study, Arzneimittel-Forschung, 42, 904
Lonergan E, 2002, Haloperidol for agitation in dementia, The Cochrane Database of Systematic Reviews, 10.1002/14651858.CD003945
UK Committee on Safety of Medicines, 2004, New advice issued on risperidone and olanapine
British Medical Association, 1995, Assessment of Mental Capacity: Guidance for Doctors and Lawyers. A Report of the British Medical Association and The Law Society